好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Identifying distinct phenotypic clusters of relapsing remitting multiple sclerosis patients using unsupervised machine learning.
Multiple Sclerosis
MS and CNS Inflammatory Disease Posters (7:00 AM-5:00 PM)
116
To identify and characterize clusters of relapsing remitting multiple sclerosis (RRMS) patients using unsupervised machine learning and objective and patient-reported outcome measures of impairment. 
Multiple sclerosis (MS) patients experience wide-ranging symptoms with varied severity across multiple domains. This heterogeneity in symptoms presents challenges for classifying patients, which has far-reaching implications for clinical trials and epidemiologic research. 
Latent profile analyses and impairment data for 2,012 RRMS patients identified distinct patient clusters using measures of upper and lower limb performance, quality of life, depression symptom severity, and perceived global disability. Multinomial logistic regression models characterized the associations for socio-demographic attributes.  

There were 6 distinct clusters of patients that differed by symptom patterns, and by their socio-demographic attributes. Most notable were were no differences in age, sex, or disease duration between the least and most impaired classes, representing 14% and 4% of patients, respectively.  Most notable findings were no difference in age, sex, or disease duration between the least and most impaired classes of patients, and that patients in the most impaired class were more likely to be Black American, have a history of smoking, have a higher BMI, and of lower SES. The results also demonstrate that the relationships between age and onset age/disease duration and symptom patterns varies, with positive relationships between age and classification to clusters of increasing moderately severe impairment but not the most severe clusters.

We identified 6 distinct clusters of RRMS patients based on shared patterns in impairment that were not known a priori but were determined empirically. By identifying phenotypic clusters, we add novel resolution to the MS phenotype, which has the potential to advance clinical trials and epidemiologic research having identified patient subgroups in whom to separately assess outcomes and associations.

 

 

Authors/Disclosures
Farren Briggs, PhD (University of Miami Miller School of Medicine)
PRESENTER
The institution of Prof. Briggs has received research support from NIH.
Devon Conway, MD Dr. Conway has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Conway has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Conway has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Conway has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen. Dr. Conway has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Conway has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Conway has received research support from Novartis. The institution of Dr. Conway has received research support from BMS. The institution of Dr. Conway has received research support from Biogen.
No disclosure on file
Daniel Ontaneda, MD, PhD, FAAN (Cleveland Clinic) Dr. Ontaneda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Ontaneda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech/Roche. Dr. Ontaneda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen Idec. Dr. Ontaneda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Dr. Ontaneda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. The institution of Dr. Ontaneda has received research support from NIH. The institution of Dr. Ontaneda has received research support from PCORI. The institution of Dr. Ontaneda has received research support from NMSS. The institution of Dr. Ontaneda has received research support from Genetech.
Doug Gunzler No disclosure on file